Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | AMY1A | P0DUB6 | 10/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | TCF4 | P15884 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712511 | 0.84 | ALPL (0.40) | ALPLALPIALPGIDO1AMY1A | |
| SCHEMBL28822617 | 0.79 | ALDH1A1 (0.37) | ALPLALPIALPG | |
| SCHEMBL29822916 | 0.79 | ALDH1A1 (0.37) | ALPLALPIALPG | |
| SCHEMBL10847755 | 0.77 | ALPL (0.35) | ALPLALPIALPGIDO1TCF4 | |
| SCHEMBL1747975 | 0.76 | ALPL (0.56) | ALPLALPIALPGIDO1AMY1A | |
| SCHEMBL229608 | 0.76 | KMT2A (0.58) | METAP2METAP1CBFB | |
| SCHEMBL1887281 | 0.76 | PLAU (0.61) | ALPLALPIALPGIDO1AMY1A | |
| SCHEMBL7590755 | 0.76 | ALDH1A1 (0.61) | ALPLALPIALPGIDO1AMY1A | |
| SCHEMBL18628747 | 0.76 | ALPL (0.56) | ALPLALPIALPGIDO1AMY1A | |
| SCHEMBL172884 | 0.76 | MEN1 (0.59) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121238173-B | Diaphragm and battery | 珠海冠宇电池股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-121261064-B | Battery cell | 珠海冠宇电池股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-121238173-B | Diaphragm and battery | 珠海冠宇电池股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-120691045-A | Lithium battery diaphragm and preparation method thereof | 天能新能源(湖州)有限公司 | 2025-09-23 | — | — | CN | disclosed |
| CN-117843579-A | Benzo heterocycle coupled catechol derivative and preparation method and application thereof | 暨南大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| US-8878165-B2 | Electrode treatment process for organic electronic devices | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20120319097-A1 | ELECTRODE TREATMENT PROCESS FOR ORGANIC ELECTRONIC DEVICES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-20 | — | — | US | disclosed |
| EP-1642899-B1 | 2,4-BIS(TRIFLUOROETHOXY)PYRIDINE COMPOUND AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2012-08-15 | — | — | EP | disclosed |
| CN-101899007-B | piperazine compounds | KOWA CO | 2012-04-25 | — | — | CN | disclosed |
| US-7176306-B2 | Hydroxyalkyl cyclic diamine compound | KOWA CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| CN-1816542-A | 2, 4-bis (trifluoroethoxy) pyridine compound and medicine containing the same | KOWA CO (JP) | 2006-08-09 | — | — | CN | disclosed |
| EP-1642899-A1 | 2,4-BIS(TRIFLUOROETHOXY)PYRIDINE COMPOUND AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-1571144-A1 | HYDROXYALKYLATED CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20050020606-A1 | 2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound | KOWA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040176593-A1 | Hydroxyalkyl cyclic diamine compound | KOWA CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| US-4950677-A | ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1990-08-21 | — | — | US | disclosed |
| US-4608381-A | ANTIARTHRITIC AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1986-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | AHR, ARNT, MTNR1A | ALPL 3848/4885ALPI 764/4885ALPG 2247/4885 |
| US-20050020606-A1 | 2,4-Bis (trifluoroethoxy)pyridine compound and drug containing the compound | ACAT2, ACAT1, CYP7A1 | ALPL 754/4885ALPI 51/4885ALPG 1266/4885 |
| US-20040176593-A1 | Hydroxyalkyl cyclic diamine compound | DDC, AOC1, ODC1 | ALPL 4578/4885ALPI 4109/4885ALPG 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.